• Autologous PRP for alopecia suffers from inherent variability due to patient-specific platelet yield, leukocyte content, and mixed stimulatory/inhibitory mediators, leading to inconsistent clinical outcomes.
• The proposed Precision Re-Engineered Efficacy Optimization framework advocates for bioengineered, growth-factor-defined platelet mimetics with batch-specified concentrations and proportions to achieve reproducible dosing and standardized potency.
• Such formulations are positioned as controlled reconstructions of selected PRP-associated signals, not complete replicas, and require rigorous characterization and staged clinical validation to establish safety, dosing, and comparative effectiveness.
• The framework holds promise for improving consistency and scalability of growth-factor-based therapies for alopecia, potentially enabling clearer clinical evaluation and more predictable outcomes.